A multivariate analysis of anti-acetylcholine receptor (AChR) antibodies and clinical parameters other than treatment (modified Osserman groups, age, type of onset, sex, and thymus pathology) was performed for all incident (n = 366) myasthenia gravis (MG) The first assays for anti-acetylcholine receptor (AChR) antibodies detected inhibition of alpha-Bungarotoxin (BuTx) binding to AChR' or complement fixation,2 but the sensitivity of those assays was less than 80%. Immunoprecipitation radioimmunoassays (RIA)35 have become the standard procedure but do not distinguish between antibodies titre and functional activity of the antibodies.6 If detergent-solubilised human AChR is used as antigen, anti-AChR antibodies are found in 75-93% of sera from patients with myasthenia gravis (MG).479 Enzyme-linked immunosorbent assay (ELISA) has only found more limited use for anti-AChR antibodies measurement.
Abstract
A multivariate analysis of anti-acetylcholine receptor (AChR) antibodies and clinical parameters other than treatment (modified Osserman groups, age, type of onset, sex, and thymus pathology) was performed for all incident (n = 366) myasthenia gravis (MG) cases in its white population in Denmark during the past 15 years. Sera from 244 healthy individuals and from 295 patients with diseases other than MG were analysed as controls. Formal statistics for the antiAChR antibodies assay (immunoprecipitation RIA using crude human AChR extract) were calculated. The distribution of antibodies titres greater than 0-1 nMolell was found to be approximately lognormal. For MG patients the 95% reference interval was 0-2-1549 nMolesIl, and in control sera the range was 00-04 nMole/l. Using 0 5 nMole/l as the cut-off level and regarding all results less than this value as normal titres, it appeared that the assay was highly specific (>99.99%) for MG. In a population of MG patients significance should be attributed to values in the range 03-0-4 nMole/l. The overall diagnostic sensitivity was found to be 88%. The sensitivity appeared to be proportionate to clinical severity of MG. The percentage with a normal titre was higher (16%) for early onset of MG, compared with 7% for late onset. No significant difference in relation to the frequency of "negative titre" was found in relation to sex. Anti-AChR antibodies titre was found to correlate with clinical severity, female or male gender, and pathology of thymus. The groups of MG patients were not matched for the various clinical parameters but multiple regression analysis controlling for these variables revealed independent effects of clinical severity and sex though not of age. Normal thymus (including involuted gland) and thymoma were correlated with low to intermediate titres, and hyperplastic thymus with high level of antibodies. The clinical implementation of anti-AChR antibodies is reviewed from 1976 and up to the present. The problems with false positive results are thoroughly expounded. (7 NeurolNeurosurg Psychiatry 1993; 56:496-504) The first assays for anti-acetylcholine receptor (AChR) antibodies detected inhibition of alpha-Bungarotoxin (BuTx) binding to AChR' or complement fixation,2 but the sensitivity of those assays was less than 80%. Immunoprecipitation radioimmunoassays (RIA) 35 have become the standard procedure but do not distinguish between antibodies titre and functional activity of the antibodies. 6 If detergent-solubilised human AChR is used as antigen, anti-AChR antibodies are found in 75-93% of sera from patients with myasthenia gravis (MG).479 Enzyme-linked immunosorbent assay (ELISA) has only found more limited use for anti-AChR antibodies measurement.
The correlation between anti-AChR antibodies titre and clinical parameters appears to be rather complex. Most studies find that the overall correlation between severity of MG and titre (single measurements in each patient) is weak. Ocular MG is associated with low titre and more antibodies negative cases than in generalised types of MG. 4810 The occurrence of thymoma has been correlated with high titre,4 low titre," or no influence on titre."2 The level of titre does not associate with the presence or absence of thymic germinal centres.'3 Age at onset of disease has been correlated with titre in some series,8"4 but not others. 4 The concentration of antibodies did not correlate with sex in some studies,4 8 but was significantly lower in males than in females in one study. 5 Explanations of these discrepancies include technical and immunological differences between the various antibodies assays; selection bias; time criteria for serum sample varying widely in relation to onset of MG and different modalities of treatment; clinical assessment not being performed at welldefined points; inclusion of non-operated cases when comparing thymus pathology and titre; significant intercorrelation between independent variables; and inappropriate statistical methods.
This study aimed at re-evaluating the clinical implementation of anti-AChR antibodies. Only the diagnostic and prognostic applications and the distribution of antibodies in relation to clinical parameters other than treatment were considered. A prospective multivariate study of the whole incident MG patient population in Denmark during the last 15 years was carried out. Strict criteria for all variables were used, and the statistical methods were chosen with emphasis on the calculation of the effect of each variable after adjustment for the other independent parameters.
Material and methods Selection of blood samples
The laboratory is the only facility in Denmark receiving sera for anti-AChR antibodies analysis. The Before examination all samples were stored at -20°C. The current results of the various assays during the decade were used. All sera were carefully titrated to assure linear relationship between CPM and volume of sample. Normal human IgG (that is, pooled serum from healthy subjects) was added as carrier to all tubes with less than 1 jul of test serum, and each result was calculated as the mean value of 2-3 linear measurements. Using the same standard positive control serum for many years, we have found the variation of the results between the single batches to be 10-20%, and accordingly all results used in this study were calibrated using this standard positive serum as reference. In the laboratory we have found virtually no loss in antibodies activity over time for samples stored in our bank.
Statistical methods and calculations
The lowest possible measurable level was 0 1 nMole/l. The two values 0 0 and 0 1 varied at random when sera showing these results were repeatedly analysed. Accordingly, it was not possible to distinguish between the case of true zeroes and that of "zeroes" which were really censored non-zero values. The frequencies of anti-AChR titres appear to be a delta distribution (fig 1) in which a proportion of the observations may be zeros and the nonzero values follow a lognormal distribution. '6 Best unbiased estimators of mean and variance were calculated according to the method of Aitchison. 16 Alternatively, antibodies titres were transformed using the base 10 logarithm, and zero values were set to 0-1 enabling them to be included in the transformation. Curve fitting (with lognormal curves) was performed using the method of the least sums of squares for the residuals.
For bodies titre as a dichotomy, normal or abnormal, appeared to be independent, though the absolute value of antibodies titres was certainly correlated to sex, see below.
The correlation between mean logarithmic antibodies titre and modified Osserman groups can be summarised as in table 5. There was no significant difference between the localised and mild groups: 1 and 2A, nor were there significant differences between the more severe cases: groups 2B, 3, and 4. Conversely, group 1 differed significantly from all other groups than 2A, and group 2A had lower mean titre than that of group 4. Figure 2 shows the increasing level of antibodies versus Osserman groups. All the significant differences also held true for female gender but not for males, a finding which may be attributable to the lower level of antibodies for males, see below.
The mean antibody level was significantly lower in sera from male patients compared with that of sera from female patients (table  6) . There was no significant difference in relation to type of onset of MG. Hyperplasia of the thymus was associated with higher antibodies concentration compared with normal thymus or thymoma (table 6). There was no significant difference between the antibody titres of patients with normal thymus and thymoma. Antibody negative cases with thymoma were not observed. Figure 2 summarises the correlation between anti-AChR antibodies titre and the clinical variables.
To estimate the possible effect of confounders, multiple regression analyses were performed. Mathematical models controlling for the different variables revealed independent effects of clinical severity and of female or male gender (table 7) . Additional calculations not including the transformed zero values showed independent effect of the same variables, proving that the log 0-1 values did not have any undue influence on the analysis. When each of the factors is used alone (table 7 , A), the most importance must be assigned to Osserman groups (standardised regression coefficient 0-28), although sex appeared to be of similar influence (-0-25). Since antibody (the dependent variable) is in log units, the coefficients can be interpreted approximately in percentage terms. Thus after statistical adjustment for the other independent variables, male antibodies titre can be estimated to be about 25% less than in females. Looking at the clinical assessment as a dichotomy, mild or severe (table 7, B), the antibodies concentration in severe MG can be estimated to be about 23% higher than in the mild cases. On the other hand, the residuals were still significant when these clinical variables were accounted for, and consequently additional factors of importance for the homeostasis and activity of the antibodies must be operative. antigen in their assay, yielding only 55% positive MG sera. Furthermore, their patient population was weighted towards higher age groups. The lognormal distribution of the anti-AChR antibodies is thus confirmed for human AChR and for a whole patient population within a country.
In table 1 the results of routine examination of 539 non-MG sera for anti-AChR antibodies are listed. A total of 150 samples were relevant unbiased controls, 473 sera came from patients with MG as a possible differential diagnosis, and 16 sera were from firstdegree relatives of MG patients, including 1 monozygotic twin sister. The high prevalence of anti-AChR antibodies (low titres) in relatives, proposed by Lefvert et al7 was not confirmed, which agrees with Vincent et al. 9 On the basis of the review of false-positive (see below) and the examination of true-negative results (table 1), the conclusion must be that the assay for anti-AChR antibodies is highly specific as a diagnostic test (table 4) . This agrees with many other studies.45891' 1819 If a conservative cut-off point is applied (that is, positive > = 0-5 nMole/l), false positive outcome is extremely rare. More significance should be attributed to values in the range 03-0A4 nMole/l in a selected population of patients in whom MG is estimated as probable and for whom relevant differential diagnoses are unlikely.
Sensitivity of the assay andfalse negative result The sensitivity of the analysis appeared to be proportionate to the clinical severity of the disease (table 4) . A negative result of the antibodies assay does not exclude MG. Antibodies negative MG cases were found to be more common for early onset of the disease than for late onset, though sex did not appear to affect the frequency of antibodies negative cases (table 4) . A few sera are positive only if the antigen is intrajunctional (normal) AChR, the antigen source is extraocular muscle, or the AChR extract is not saturated with BuTx.920 Anti-AChR antibodies which bind to the BuTx site of the receptor can be demonstrated in more than 30% of MG sera,l but these are the only anti-AChR antibodies demonstrable in just a few per cent of MG sera.'8 The RIA can be modified to detect these antibodies reliably.'8 Other modified protocols further reduce the proportion of antibodies negative cases.9 The use of heterologous AChR reduces positivity; sensitivity with rat AChR is 55%,13 fetal calf AChR 74%,14 and with monkey AChR 29%-79%.
False positive result Biological false-positive results appear to be rather infrequent. Low titre positive outcome has been reported in non-MG patients: amyotrophic lateral sclerosis;22-24 penicillaminetreated patients without MG;8 25 thymoma without MG;8 9 26 neonates to anti-AChR antibodies positive MG mothers;27 bone marrow transplantation;28 elderly and Down's syndrome Japanese but not white subjects;2930 tardive dyskinesia;" patients with high antithyroid autoantibodies (borderline titres);30 primary biliary cirrhosis and patients with mitochondrial antibody.32 The sera from many of these patients are not false-positive in a true sense, and this matter will be reviewed in the following paragraphs.
In first-degree relatives of MG patients the prevalence of anti-AChR antibodies (low titres) and anti-idiotypic-AChR antibodies was found to be 54% and 37% respectively. '7 The natural occurrence of anti-idiotypicAChR antibodies has been disputed."
Furthermore, this high incidence of positivity in relatives has not been confirmed by this study or by other groups.9 One out of three monozygotic twins (without clinical MG) to female MG patients was anti-AChR antibodies positive.9
False-positive immunoassay for anti-AChR antibodies has been reported for 19 of a total of 171 cases with amyotrophic lateral sclerosis (ALS).22-24 A closer look reveals that no anti-AChR antibodies were found in 10 of these cases; the antibodies were crossreacting with BuTx, which could be attributed to experimental snake venom therapy in all cases.22 24 Two of these patients exhibited decremental response on electromyography and also clinical signs in accordance with MG,2324 so they may well be diagnosed as having MG as well as ALS. Of the remaining 7 patients, very low titre (0 1-0 4 nMole/l) was found in 5 cases and low titre (0-8 and 4-1 nMoles/l) in 2 cases. No follow up data have been published for these patients. In Denmark we have found no ALS cases with significant anti-AChR antibodies titres (table 1) .
Anti-AChR antibodies in penicillaminetreated patients without MG were first reported in 1980,25 but no follow up data are available. Since 1975 it has been known that MG could be induced by penicillamine in patients with rheumatoid arthritis. 34 The fine specificities of the anti-AChR antibodies in sera from these patients do not differ from the antibodies in sera from idiopathic MG. 35 Penicillamine probably produces MG by initiating a new autoimmune response in most of these cases rather than by enhancing ongoing autoimmunity. Usually antibody levels fall rapidly after stopping penicillamine treatment. 35 The author has diagnosed 5 penicillamine-induced MG cases in Denmark since 1980. In 4 of these cases the clinical signs of MG disappeared within 5 months after penicillamine treatment was discontinued, and serial measurements showed decrease in the anti-AChR antibodies titres during the same period of time. Ultimately the antibodies could no longer be detected. In one case the antibodies level and the clinical condition did not change during a follow up period of 4 years, proving that in some cases the association between penicillamine and MG could be due to chance or autoimmune predisposition.
Further evidence for this view is the co-existence of MG, rheumatoid arthritis, or other autoimmune diseases in the absence of penicillamine-treatment.'6 Until now we have not found anti-AChR antibodies in penicillaminetreated patients without MG in Denmark.
Other case histories with chemically induced autoimmunity have been published by Lieberman et al,31 who examined sera from 34 patients with neuroleptic-induced tardive dyskinesia. Three sera had anti-AChR antibodies titre with range 0-8-1 *4, and 12 sera were in the range 0 3-0 5. It is not stated whether the patients presented MG symptoms or not. The titres were inversely correlated to the period of time off neuroleptics. At least 9 out of the 29 psychiatric cases examined in our laboratory (table 1) were on neuroleptics at the time of sample collection and the other 20 patients had discontinued such a treatment shortly before, but all 29 sera were "0-0" negative.
Anti-AChR antibodies have also been reported in a few sera from non-MG patients with thymoma.8926 A systematic examination of this topic has not been published. In larger series of operated thymomas 53%-73% were also diagnosed as MG,'738 and other autoimmune diseases were manifest in 7% of the patients in the series. 37 The period between the finding of thymoma and the onset of MG may be up to 10 years.39 Accordingly the occurrence of anti-AChR antibodies in non-MG thymoma cases may possibly anticipate later development of MG symptoms.
Anti-AChR antibodies were found in 11 out of 54 (20%) bone marrow transplanted (BMT) patients.28 Some of these patients developed MG 1-3 years after allogeneic BMT. The titres in the non-MG patients were low (0-3-4-8 nMoles/l), and the antibodies response was transient in 4 cases. Graftversus-host disease has been implicated, and in one of the cases with MG after BMT the autoimmune disease was probably of donor origin.28
Methodological details and thus the values obtained for AChR binding by normal sera differ in various laboratories. Nevertheless, great care should be taken in the assignment of "false-positive" to an anti-AChR antibodies titre >0 4 nMole/l. Garlepp et aP9 have argued for a symptomatic threshold. They followed a patient with MG and Graves' disease during 5 years. Both before MG symptoms and after remission a low anti-AChR antibodies titre was found, and during the active phase of MG the titre was approximately 3 times higher. Further evidence for the concept of a symptomatic threshold is that significant levels of anti-AChR antibodies may also be found after remission of MG. 
